Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is BML Capital Management LLC's 3rd Largest Position

BML Capital Management LLC grew its holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 4.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,650,000 shares of the company's stock after acquiring an additional 274,379 shares during the quarter. Atea Pharmaceuticals accounts for 13.1% of BML Capital Management LLC's portfolio, making the stock its 3rd largest holding. BML Capital Management LLC owned approximately 7.88% of Atea Pharmaceuticals worth $22,278,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in AVIR. Dimensional Fund Advisors LP boosted its holdings in shares of Atea Pharmaceuticals by 55.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 594,360 shares of the company's stock worth $1,968,000 after purchasing an additional 211,428 shares in the last quarter. Marshall Wace LLP acquired a new stake in Atea Pharmaceuticals during the 2nd quarter worth $603,000. Almitas Capital LLC acquired a new stake in shares of Atea Pharmaceuticals in the second quarter valued at approximately $4,271,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Atea Pharmaceuticals during the 1st quarter valued at $123,000. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Atea Pharmaceuticals by 21.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 67,137 shares of the company's stock worth $272,000 after purchasing an additional 11,968 shares during the last quarter. Institutional investors own 86.67% of the company's stock.

Atea Pharmaceuticals Trading Down 0.9 %

AVIR stock traded down $0.03 during mid-day trading on Tuesday, reaching $3.33. The company's stock had a trading volume of 265,329 shares, compared to its average volume of 298,995. The company has a market cap of $281.12 million, a price-to-earnings ratio of -1.65 and a beta of 0.17. Atea Pharmaceuticals, Inc. has a 12 month low of $2.77 and a 12 month high of $4.60. The business's 50 day moving average price is $3.53 and its 200 day moving average price is $3.61.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.13. During the same period in the previous year, the business posted ($0.40) earnings per share. As a group, equities analysts expect that Atea Pharmaceuticals, Inc. will post -2.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AVIR has been the subject of a number of analyst reports. Morgan Stanley raised Atea Pharmaceuticals from an "underweight" rating to an "equal weight" rating and increased their price target for the company from $2.00 to $6.88 in a research report on Tuesday, August 13th. William Blair raised Atea Pharmaceuticals to a "strong-buy" rating in a research report on Friday, August 30th.

Insider Buying and Selling at Atea Pharmaceuticals

In other news, CEO Jean-Pierre Sommadossi sold 33,941 shares of the firm's stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $4.05, for a total transaction of $137,461.05. Following the completion of the transaction, the chief executive officer now directly owns 5,890,053 shares in the company, valued at $23,854,714.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 17.80% of the company's stock.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.